MRK catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
December 2026
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Dec 22, 2026Sponsor estimate | NCT05468697A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell...Merck Sharp & Dohme LLC · Renal Cell Carcinoma | MRKLead | Phase 1/Phase 2 | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Dec 22, 2026Sponsor estimatePhase 1/Phase 2NCT05468697A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell...Merck Sharp & Dohme LLC · Renal Cell CarcinomaActive, not recruitingMRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
February 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Feb 12, 2027Sponsor estimate | NCT03407144Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)Merck Sharp & Dohme LLC · Hodgkin Lymphoma | MRKLead | Phase 2 | Active, not recruiting | Locked | Locked | Locked |
| Feb 17, 2027Sponsor estimate | NCT07486960Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)Merck Sharp & Dohme LLC · Psoriatic Arthritis | MRKLead | Phase 2 | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Feb 12, 2027Sponsor estimatePhase 2NCT03407144Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)Merck Sharp & Dohme LLC · Hodgkin LymphomaActive, not recruitingMRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 17, 2027Sponsor estimatePhase 2NCT07486960Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)Merck Sharp & Dohme LLC · Psoriatic ArthritisActive, not recruitingMRKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 3 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.